INmune Bio Inc. (NASDAQ:INMB) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, INMB to report 3Q20 loss of $ 0.17 per share.
For the full year, analysts anticipate loss of $ 0.75 per share bottom line.
Stock Performance
Shares of INmune Bio Inc. traded up $ 0.19 or 2.35 percent on Wednesday, reaching $ 8.28 with volume of 127.50 thousand shares. INmune Bio Inc. has traded high as $ 8.70 and has cracked $ 7.88 on the downward trend
The closing price of $ 8.28, representing a 267.73 % increase from the 52 week low of $ 2.20 and a 66.87 % decrease over the 52 week high of $ 24.42.
The company has a market capital of $ 111.35 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
INmune Bio Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.inmunebio.com
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patients innate immune system to treat cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood; and XPro1595 for the treatment of Alzheimers disease.
